Literature DB >> 32548165

Macrophage activation syndrome as a complication of dermatomyositis: A case report.

Ding-Xian Zhu1, Jian-Jun Qiao1, Hong Fang2.   

Abstract

BACKGROUND: Macrophage activation syndrome (MAS) can be a fatal complication of rheumatic disorders, which occurs most commonly in patients with systemic juvenile idiopathic arthritis or systemic lupus erythematosus. It has rarely been reported in patients with dermatomyositis. Here, we describe a fatal case of MAS that developed in an adult patient with dermatomyositis. CASE
SUMMARY: A 44-year-old woman was admitted to our hospital with fever, generalized rash and muscle weakness. Fifteen days later, the fever persisted after the use of antibiotics, and repeat blood culture was negative. The patient then exhibited a typical Gottron sign and diffuse erythema on the face and neck, which were consistent with a diagnosis of dermatomyositis. The patient exhibited limb muscle strength of 2, and electromyography was suggestive of muscle-derived damage, which also supported a diagnosis of dermatomyositis. In addition, the patient exhibited high serum ferritin level, cytopenia, liver dysfunction, coagulopathy, enlarged spleen and hypertriglyceridemia, all of which are typical manifestations of MAS. The patient was diagnosed with dermatomyositis complicated by MAS. Although a high dose of methylprednisolone was administered for 15 d, the patient's condition continued to deteriorate and central nervous system symptoms developed. Eventually, treatment was discontinued, and the patient died.
CONCLUSION: MAS is an important, potentially fatal, complication of dermatomyositis. Although MAS is rare in dermatomyositis, it should be considered in the differential diagnosis of an unexplained change of hemoglobin, platelet, fibrinogen, ferritin and triglyceride, which may complicate dermatomyositis. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Case report; Dermatomyositis; Hyperferritinemia; Inflammatory; Macrophage activation syndrome; Systemic juvenile idiopathic arthritis

Year:  2020        PMID: 32548165      PMCID: PMC7281037          DOI: 10.12998/wjcc.v8.i11.2339

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  20 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Authors:  Angelo Ravelli; Francesca Minoia; Sergio Davì; AnnaCarin Horne; Francesca Bovis; Angela Pistorio; Maurizio Aricò; Tadej Avcin; Edward M Behrens; Fabrizio De Benedetti; Lisa Filipovic; Alexei A Grom; Jan-Inge Henter; Norman T Ilowite; Michael B Jordan; Raju Khubchandani; Toshiyuki Kitoh; Kai Lehmberg; Daniel J Lovell; Paivi Miettunen; Kim E Nichols; Seza Ozen; Jana Pachlopnik Schmid; Athimalaipet V Ramanan; Ricardo Russo; Rayfel Schneider; Gary Sterba; Yosef Uziel; Carol Wallace; Carine Wouters; Nico Wulffraat; Erkan Demirkaya; Hermine I Brunner; Alberto Martini; Nicolino Ruperto; Randy Q Cron
Journal:  Ann Rheum Dis       Date:  2016-03       Impact factor: 19.103

3.  Severe macrophage activation syndrome and central nervous system involvement in juvenile dermatomyositis.

Authors:  V Lilleby; J Haydon; H Sanner; B K Krossness; G Ringstad; B Flatø
Journal:  Scand J Rheumatol       Date:  2014       Impact factor: 3.641

4.  Fatal case of macrophage activation syndrome (MAS) in a patient with dermatomyositis and cytomegalovirus (CMV) viraemia.

Authors:  Allison Virginia Lange; Salahuddin Kazi; Weina Chen; Arti Barnes
Journal:  BMJ Case Rep       Date:  2018-07-30

5.  Epidemiologic features of diffuse connective tissue disorders in Rochester, Minn., 1951 through 1967, with special reference to systemic lupus erythematosus.

Authors:  L T Kurland; W A Hauser; R H Ferguson; K E Holley
Journal:  Mayo Clin Proc       Date:  1969-09       Impact factor: 7.616

Review 6.  Macrophage activation syndrome in juvenile dermatomyositis: a systematic review.

Authors:  Dimitri Poddighe; Kaisar Dauyey
Journal:  Rheumatol Int       Date:  2019-09-16       Impact factor: 2.631

Review 7.  Similar but not the same: Differential diagnosis of HLH and sepsis.

Authors:  Rafał Machowicz; Gritta Janka; Wieslaw Wiktor-Jedrzejczak
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-23       Impact factor: 6.312

8.  Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis.

Authors:  Shinjiro Kaieda; Naomi Yoshida; Fumiya Yamashita; Masaki Okamoto; Hiroaki Ida; Tomoaki Hoshino; Takaaki Fukuda
Journal:  Mod Rheumatol       Date:  2013-10-21       Impact factor: 3.023

9.  Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.

Authors:  Yu Zuo; Lifang Ye; Min Liu; Shanshan Li; Weifang Liu; Fang Chen; Xin Lu; Patrick Gordon; Guochun Wang; Xiaoming Shu
Journal:  Rheumatology (Oxford)       Date:  2020-10-01       Impact factor: 7.580

Review 10.  Understanding organ dysfunction in hemophagocytic lymphohistiocytosis.

Authors:  Caroline Créput; Lionel Galicier; Sophie Buyse; Elie Azoulay
Journal:  Intensive Care Med       Date:  2008-04-22       Impact factor: 41.787

View more
  2 in total

1.  Identification of hub biomarkers and immune cell infiltration in polymyositis and dermatomyositis.

Authors:  Si Chen; Haolong Li; Haoting Zhan; Xiaoli Zeng; Hui Yuan; Yongzhe Li
Journal:  Aging (Albany NY)       Date:  2022-05-24       Impact factor: 5.955

2.  Macrophage activation syndrome in MDA5 antibody-positive dermatomyositis and COVID-19 infection.

Authors:  Marzieh Keshtkarjahromi; Sumit Chhetri; Amulya Balagani; Umm-Ul-Banin B Tayyab; Christopher J Haas
Journal:  BMC Rheumatol       Date:  2021-12-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.